Evidence map›Paper›PMID 40890399›Full record

ArticleInternational journal of clinical oncology2025

Efficacy and safety of talaporfin sodium photodynamic therapy as a salvage treatment for locally recurrent esophageal squamous cell carcinoma.

Mamoru Tanaka, Makiko Sasaki, Hirotada Nishie, Yuki Kojima, Yasunari Sasaki, Taketo Suzuki, Shigeki Fukusada, Naomi Sugimura, Keiji Ozeki, Takaya Shimura and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Mamoru TanakaDepartment of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Science, Nagoya, Aichi, Japan. mtanaka@med.nagoya-cu.ac.jp.ORCID http://orcid.org/0000-0001-8416-5774
Makiko SasakiDepartment of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Science, Nagoya, Aichi, Japan.
Hirotada NishieDepartment of Gastroenterology, Nagoya City University Midori Municipal Hospital, Nagoya, Aichi, Japan.
Yuki KojimaDepartment of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Science, Nagoya, Aichi, Japan.
Yasunari SasakiDepartment of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Science, Nagoya, Aichi, Japan.
Taketo SuzukiDepartment of Gastroenterology, Nagoya City University Midori Municipal Hospital, Nagoya, Aichi, Japan.
Shigeki FukusadaDepartment of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Science, Nagoya, Aichi, Japan.
Naomi SugimuraDepartment of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Science, Nagoya, Aichi, Japan.
Keiji OzekiDepartment of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Science, Nagoya, Aichi, Japan.
Takaya ShimuraDepartment of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Science, Nagoya, Aichi, Japan.
Eiji KubotaDepartment of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Science, Nagoya, Aichi, Japan.
Hiromi KataokaDepartment of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Science, Nagoya, Aichi, Japan.

Funding

Bristol Myers Squibb Foundation JOSE202103Japan Society for the Promotion of Science 20K16997Japan Society for the Promotion of Science 22K16050Japan Society for the Promotion of Science 22K20862Japan Society for the Promotion of Science 23K07358Japan Society for the Promotion of Science 23K07421Japan Society for the Promotion of Science 23K15019The Nitto Foundation JOSE206093Toyoaki Scholarship Foundation JOSE203179
6 · The paper itself

Abstract

backgroundEsophageal squamous cell carcinoma (ESCC) presents significant treatment challenges, with chemoradiotherapy (CRT) leading to local recurrence in 30-40% of cases. Limitations of traditional salvage therapies have driven interest in photodynamic therapy with talaporfin sodium (TS-PDT), a minimally invasive treatment with reduced phototoxicity, which has been increasingly utilized since its approval in Japan.

methodsThis retrospective study at the Nagoya City University Hospital (May 2016-December 2023) assessed the efficacy of TS-PDT for esophageal cancer after CRT or radiotherapy in 29 patients who met specific inclusion criteria. The evaluated outcomes included adverse events, local complete response (L-CR), progression-free survival (PFS), and overall survival (OS).

resultsAmong the patients (23 men and 6 women; median age, 72 years), TS-PDT achieved an L-CR rate of 81.5% per patient and 87.8% per lesion, with a higher success rate against T1b lesions. The median local PFS was 44.1 months, and OS had not yet been reached, with a 1-year survival rate of 91.9%. The adverse events included esophageal strictures and perforations.

conclusionTS-PDT is a potentially effective salvage treatment for ESCC, offering efficient local control and favorable survival outcomes. Despite some adverse events, its reduced phototoxicity and versatility make it a viable option, particularly for elderly patients. Further multicenter trials are warranted to validate its role in esophageal cancer management.

Indexed as

Esophageal NeoplasmsEsophageal Squamous Cell CarcinomaNeoplasm Recurrence, LocalPhotochemotherapyPhotosensitizing AgentsPorphyrinsSalvage TherapyAgedAged, 80 and overFemaleHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomePhotosensitizing AgentsPorphyrinsTalaporfinChemoradiotherapyEsophageal squamous cell carcinomaLocal recurrenceOverall survivalPhotodynamic therapyProgression-free survivalSalvage treatmentTalaporfin sodium

Identifiers

PMID40890399

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.